EndoForce Connector for Endovascular Venous Anastomosis
Phraxis, Inc. · Decision date Jul 18, 2025
What did the FDA approve?
FDA records P240004/S001 as a supplement to PMA P240004, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 18, 2025.
FDA approval order statement
Approval of the protocol for the EndoForce Post-Approval Study submitted to comply with the conditions of approval outlined in the approval order for P240004.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 18, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P240004/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Phraxis, Inc.
- Product code
- SEQ
- Decision code
- APPR
- Decision date
- Jul 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Covered stent vascular connector, hemodialysis access circuit.
- Applicant
- Phraxis, Inc.
- Product code
- SEQ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P240004/S001 received
Application receipt date recorded by FDA.
P240004/S001 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P240004. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Phraxis, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 333 Hennepin Ave. E., Minneapolis, MN, 55114
Sources and methodology
- Original FDA record: P240004/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records